Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 15/20 | 0.45 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.38 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.37 |
| ▸ | CSF1R | P07333 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13468559 | 0.91 | CRHR1 (0.38) | EZH2CRHR1 | |
| SCHEMBL15710286 | 0.88 | EZH2 (0.42) | EZH2HCRTR1HCRTR2CSF1R | |
| SCHEMBL17804344 | 0.87 | EZH2 (0.43) | EZH2CRHR1 | |
| SCHEMBL13280030 | 0.87 | EZH2 (0.43) | EZH2CRHR1 | |
| SCHEMBL13279900 | 0.83 | EZH2 (0.61) | EZH2 | |
| SCHEMBL13280137 | 0.79 | EZH2 (0.46) | EZH2HCRTR1HCRTR2 | |
| SCHEMBL13279996 | 0.78 | CRHR1 (0.38) | EZH2CRHR1 | |
| SCHEMBL18830476 | 0.78 | CRHR1 (0.38) | EZH2CRHR1 | |
| SCHEMBL15710346 | 0.77 | ALDH1A1 (0.38) | EZH2 | |
| SCHEMBL15710122 | 0.76 | ALDH1A1 (0.36) | EZH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3470396-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. (US) | 2019-04-17 | — | — | EP | disclosed |
| EP-3165520-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme Inc (US) | 2017-05-10 | — | — | EP | disclosed |
| US-9376422-B2 | Dihidropyridin-2-one benzamine compounds | Epizyme, Inc. (US) | 2016-06-28 | — | — | US | disclosed |
| US-20140142083-A1 | Substituted Benzene Compounds | Epizyme, Inc. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140142083-A1 | Substituted Benzene Compounds | Epizyme, Inc. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140142083-A1 | Substituted Benzene Compounds | Epizyme, Inc. (US) | 2014-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140142083-A1 | Substituted Benzene Compounds | CYP1B1, TP53, VHL | EZH2 2519/4885HCRTR1 3281/4885HCRTR2 3113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.